Trevi Therapeutics, Inc.

NASDAQ:TRVI

Biotechnology

Healthcare
$13.51 +2.63%

+$0.43 today

Market cap
$1.93B
Beta
1.05
P/E (TTM)
-53.6
EPS (TTM)
-$0.31
52W Low $5.41High $17.10

Volume 2.02M

Average 1.44M

TRVI Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Trevi Therapeutics, Inc.NASDAQ: TRVI

Financing Cash Flow · Q3 FY2026 · quarter ended Sep 2026

Financing cash flow declines year over year

Q3 FY2026 financing cash flow of $412K fell 74.7% year over year, behind the -4.0% change in trailing-twelve-month financing cash flow. Sequentially, it fell 99.7% from the prior quarter. Over 3 fiscal years it compounded at +2.8% a year.

Context

  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -74.7% toward the trailing-twelve-month pace of -4.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$412K-99.7% QoQ
Last fiscal yearDec 2025
$121.01M+96.8% YoY
LTMSep 2026
$165.28M-4.0% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-74.7%——
1 year+96.8%——
3-year CAGR+2.8%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
121.01M USD
Year-over-year change
+96.8%
4-year CAGR
+55.4%

Financing Cash Flow vs competitors

How TRVI compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -4.0% is the 5th highest of 9, against a peer median of +11.7%.
  • Over three fiscal years its annual growth of +2.8% compares with a peer median of +32.0%.
TRVI Competitors
Financing Cash Flow for TRVI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VCREVicore Pharma Holding ABLTM Jun 2026SEK 430.53M SEK-48.4%+32.0%32371.3%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$271.31M USD+71.7%+89.7%1356.6%
TRVITrevi Therapeutics, Inc.LTM Sep 2026$165.28M USD-4.0%+2.8%—
ACADACADIA Pharmaceuticals Inc.LTM Jun 2026$51.05M USD+154.8%+82.6%4.5%
TENXTenax Therapeutics, Inc.LTM Mar 2026$45.45M USD-60.7%+65.1%—
LQDALiquidia CorporationLTM Jun 2026$40.85M USD-75.7%-2.8%9.1%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$40.83M USD+2642.3%—58.6%
TBPHTheravance Biopharma, Inc.LTM Mar 2026$7.97M USD+387.5%-83.8%7.3%
UPBUpstream Bio, Inc.LTM Mar 2026$3.07M USD-99.2%-37.4%92.5%
Peer median (excluding TRVI) —+11.7%+32.0%58.6%

Competitors are the stored peer set for TRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(33.94M)(29.15M)(29.07M)(47.91M)(42.76M)
Depreciation & Amortization50K43K123K147K144K
Deferred Income Tax(82K)0000
Stock-Based Compensation2.54M2.33M2.25M3.59M5.19M
Change in Working Capital1.51M(1.23M)(3.85M)6.83M(3.49M)
Accounts Receivables00000
Inventory00000
Accounts Payables831K9K(1.05M)1.61M(598K)
Other Working Capital678K(1.24M)(2.8M)5.22M(2.89M)
Other Non-Cash Items974K(162K)(1.17M)(907K)(1.17M)
Operating Cash Flow(28.95M)(28.18M)(31.71M)(38.26M)(42.09M)
Capital Expenditures0(159K)(137K)(35K)(12K)
Acquisitions (Net)0(829K)000
Purchases of Investments0(126.22M)(9.93M)(98.46M)(170.66M)
Sales of Investments019M69.5M75.6M74.93M
Other Investing Activities0829K01.37M1.64M
Investing Cash Flow0(107.37M)59.43M(21.53M)(94.11M)
Debt Repayment(68K)(5.83M)(9.41M)(126K)0
Common Stock Issued21.18M105.41M1.71M61.15M120.3M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(340K)11.73M(211K)464K714K
Financing Cash Flow20.78M111.31M(7.91M)61.48M121.01M
Effect of Forex Changes00000
Net Change in Cash(8.17M)(24.24M)19.81M1.7M(15.18M)
Free Cash Flow(28.95M)(28.33M)(31.85M)(38.29M)(42.1M)

Trevi Therapeutics, Inc.

NASDAQ:TRVI

Intrinsic Alpha fair value

Locked

Current Price

$13.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.